HHS recommendation to reschedule cannabis keeps pot stocks hot, but questions remain

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 34 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 97%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

The DEA is not bound to follow the U.S. Health and Human Services Department's recommendation to reclassify marijuana as a Schedule III drug.

The move by the Drug Enforcement Administration to review the Schedule I classification for cannabis sparked a wave of speculation and mostly positive comments from Wall Street on Thursday, but many questions remain.

Cresco Labs CRLBF, +11.29% was rallying by 9.4%, Green Thumb Industries GTBIF, +16.22% was up by 10.5% and Trulieve Cannabis TCNNF, +21.41% was up by 13.7%. During a Senate hearing in March, Garland reiterated a statement he made at his confirmation hearing that the Justice Department’s position on cannabis will be “very close to what was done” in the Cole memorandum, which was a policy put in place in 2013 that limited the role of federal law-enforcement regarding cannabis.

It’s also widely agreed that the Food and Drug Administration would be poised to regulate cannabis, but uncertainties remain over what that would look like, Zuanic said.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 3. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Pot stocks rally after health officials ask DEA to reclassify marijuana as lower-risk drugAssistant Secretary for Health Rachel Levine reportedly requested in a letter to DEA Administrator Anne Milgram that marijuana be downgraded to a schedule III substance.
출처: FoxBusiness - 🏆 458. / 53 더 많은 것을 읽으십시오 »